Background
• To qualitatively explore MS patients' experiences with DMTs
Objective
• Disease modifying therapies (DMTs) may reduce relapse rates and delay disease progression among multiple sclerosis (MS) patients; 1 however, good adherence is necessary to achieve optimal clinical benefit. 2 • Adherence to DMTs is suboptimal with rates range from 41 to 88 percent. 3 • Understanding patients' experiences with DMT may help to identify barriers of adherence as well as lead to the development of patient-centered adherence interventions.
Methods
• Study Design: -Qualitative investigation using focus groups (FGs) 
Barriers of Adherence
• Four major themes emerged: 1) DMTrelated issues, 2) barriers of adherence, 3) facilitators of adherence (currently used), and 4) facilitators of adherence (desired).
• Some sub-themes differed between participants taking injectable and oral DMTs.
• Overall, DMT-related issues contributed to medication burden for patients rather than directly impacting adherence.
• Patients experienced some issues that directly impacted adherence (barriers of adherence).
• Patients utilized various strategies and techniques (facilitators of adherence) to overcome DMT-related issues and barriers of adherence. • Social desirability bias may have influenced responses.
• Data saturation may not have been met after the three FGs.
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